Wegovy vs Ozempic for Weight Loss: Same Drug, Different Label

Reviewed by Dr. Sarah Mitchell, PhD, Biochemistry
Topics: GLP-1 Semaglutide Weight Loss
Wegovy vs Ozempic for Weight Loss: Same Drug, Different Label
⚠️ Research Disclaimer: This content is for educational purposes only. All compounds discussed are research peptides. Consult a qualified healthcare professional before considering any protocol.

Wegovy and Ozempic are both semaglutide — the same molecule in the same once-weekly injectable form. What differs is the label, the dose ceiling, the clinical program behind FDA approval, and the insurance infrastructure. This review walks through those differences in research context, because knowing the drug is the same but the label is not changes how patients make the choice.

Key Takeaways

  • Same molecule. Both Wegovy and Ozempic are semaglutide. The active drug is identical.
  • Different FDA indications. Ozempic is approved for type 2 diabetes; Wegovy for chronic weight management (BMI ≥27 with comorbidity or BMI ≥30).
  • Different dose ceilings. Ozempic maxes at 2.0 mg weekly; Wegovy maxes at 2.4 mg weekly.
  • Different clinical programs. Ozempic was approved based on SUSTAIN (glycemic + cardiovascular); Wegovy on STEP (weight loss).
  • Different insurance coverage. Ozempic is often covered for T2D; Wegovy is often not covered for weight loss unless a specific obesity benefit exists.
  • Cost gap narrowing. List prices are similar; out-of-pocket differs mainly because of insurance.

Same molecule, two SKUs

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. The company sells it under three brand names in the US: Ozempic (injectable, T2D), Wegovy (injectable, chronic weight management), and Rybelsus (oral, T2D). The active pharmaceutical ingredient in Ozempic and Wegovy is chemically identical. The excipients (buffers, preservatives) in the injectable formulations are substantially the same. The physical pens look nearly identical to the eye.

What differs is the label. Novo Nordisk ran two parallel Phase 3 programs: SUSTAIN for T2D (which became Ozempic) and STEP for obesity (which became Wegovy). The programs tested different doses and different endpoints in different populations, which is why the FDA approvals ended up as two different products.

Dose ceiling and titration

The clinically important difference is the top dose:

SpecOzempicWegovy
FDA indicationType 2 diabetes (± CV benefit)Chronic weight management (BMI ≥27 + comorbidity, or BMI ≥30)
Starting dose0.25 mg weekly × 4 weeks0.25 mg weekly × 4 weeks
Available dose steps0.25, 0.5, 1.0, 2.0 mg0.25, 0.5, 1.0, 1.7, 2.4 mg
Maintenance / top dose1.0 mg (common) or 2.0 mg (max)2.4 mg
Pivotal trialSUSTAIN programSTEP program
Average weight loss at top dose, 68 wk~6–8% (SUSTAIN populations)~15% (STEP-1)

The 2.4 mg Wegovy dose is why weight-loss outcomes are better on Wegovy than on Ozempic for the same patient. Semaglutide weight loss scales roughly linearly with dose, and 2.4 mg exposes the patient to roughly 20% more drug per week than 2.0 mg Ozempic.

Clinical programs and populations

The patient populations in SUSTAIN and STEP differ in ways that matter for interpretation:

ProgramPopulationPrimary endpointWhy it matters
SUSTAIN-1 through -10Adults with T2DHbA1c reductionDose-finding driven by glucose, not weight
SUSTAIN-6T2D with high CV riskMACE (major adverse CV events)Established CV benefit at 1.0 mg weekly
STEP-1Adults with obesity, no T2D% body weight change at 68 weeksEstablished 15% average weight loss at 2.4 mg
STEP-2Adults with obesity + T2D% body weight change at 68 weeksShowed somewhat lower loss in T2D (~10%)
STEP-5Long-term maintenance 104 weeksSustained weight lossShowed persistence of effect over 2 years

Insurance and cost

In the US, insurance behavior is often the single biggest practical difference between Ozempic and Wegovy:

  • Ozempic for T2D is widely covered by commercial insurance and Medicare Part D. Prior authorization is sometimes required but is routine.
  • Wegovy for weight loss is covered by far fewer commercial plans. Medicare does not cover anti-obesity medications under current statute (as of 2026 — this is a moving target).
  • Off-label Ozempic for weight loss is common but shrinking. Payers have increasingly tightened prior authorization to prevent off-label use.
  • List prices are in the same range (approximately $1,000–$1,350 monthly), but out-of-pocket for Wegovy without obesity coverage can run $1,000+ per month cash.

The practical result: patients with T2D often get Ozempic covered easily and may hesitate to switch to Wegovy even for better weight loss, because coverage drops out from under them.

Can you get weight loss on Ozempic?

Yes — Ozempic 1.0 mg and 2.0 mg produce meaningful weight loss in SUSTAIN. But the Phase 3 average at Ozempic 2.0 mg is roughly half the Wegovy 2.4 mg endpoint, because:

  • Dose ceiling is lower (2.0 vs 2.4 mg).
  • SUSTAIN populations have T2D, which blunts semaglutide weight loss by about 30% versus non-T2D populations.

For a non-diabetic patient wanting maximum weight loss, Wegovy at 2.4 mg is the correct product on efficacy grounds. For a T2D patient needing glycemic control plus modest weight loss, Ozempic at 1.0 or 2.0 mg is the right call.

Switching between them

Switching between Ozempic and Wegovy at the same dose (e.g., Ozempic 1.0 mg → Wegovy 1.0 mg) is pharmacologically identical and does not require re-titration. Moving from Ozempic 2.0 mg → Wegovy 2.4 mg is a single step up and usually tolerated. The reason for a switch is almost always insurance change (gaining or losing obesity coverage) or dose-ceiling reasons (wanting the extra 2.4 mg step).

Conclusion

Wegovy and Ozempic are the same drug under two labels. The clinically important difference is the top dose (2.4 vs 2.0 mg), and the practical difference is insurance coverage. For maximum weight loss, Wegovy at 2.4 mg is the correct product; for glycemic control in T2D (with modest weight loss as a bonus), Ozempic at 1.0–2.0 mg is the correct product. Picking between them is less about pharmacology and more about which product your insurer actually pays for — and that is a conversation to have with the prescriber and the pharmacy before the first script is written.

Frequently Asked Questions

Are Wegovy and Ozempic the same drug?

Yes. Both contain semaglutide as the active ingredient. The injectable formulations are substantially identical.

Which is better for weight loss, Wegovy or Ozempic?

Wegovy, because it is approved for up to 2.4 mg weekly compared to 2.0 mg for Ozempic. STEP-1 showed ~15% average weight loss on Wegovy 2.4 mg vs ~6–8% for Ozempic 2.0 mg in T2D populations.

Why is Wegovy more expensive out of pocket?

Because many insurance plans cover Ozempic for T2D but exclude Wegovy for weight loss. List prices are similar; patient cost depends on coverage.

Can I switch from Ozempic to Wegovy?

Yes, typically at the same dose level. Moving from Ozempic 2.0 to Wegovy 2.4 is a single step up and does not usually require re-titration.

Is Wegovy covered by Medicare?

As of 2026, Medicare generally does not cover anti-obesity medications. Policy is in flux and this may change.

Can Ozempic be prescribed for weight loss?

Off-label, yes. In practice, payer prior authorization has tightened and off-label coverage for weight loss is increasingly limited.


Primary sources:

Research disclaimer: This article is a research review for educational use only. It is not medical advice and should not be used to make treatment decisions. Insurance coverage changes frequently; verify current benefit with your plan. Discuss any choice between Ozempic and Wegovy with a qualified prescriber.

Sources & Further Reading

Peer-reviewed clinical trial data and research publications underpinning this article. See our full research library.

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384:989–1002. Phase 3 RCT
  2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 389:2221–2232. Phase 3 RCT